Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the provided label excerpts, especially indication and ingredient/class identification. Some mechanism/administration details are broadly consistent with label language, but the response omits key labeled administration elements (dose, priming specifics, mouth rinsing) and does not reflect additional labeled safety warnings (e.g., pneumonia vigilance, antifungal treatment approach).
Category Scores
Accurate Statements
Breztri Aerosphere is a combination inhaler containing three active pharmaceutical ingredients: budesonide, glycopyrrolate, and formoterol fumarate.
11 DESCRIPTION: "BREZTRI AEROSPHERE (budesonide, glycopyrrolate and formoterol fumarate) Inhalation Aerosol..."
Budesonide is an inhaled corticosteroid (ICS).
11 DESCRIPTION: "micronized budesonide [an inhaled corticosteroid (ICS)]"
Glycopyrrolate is a long-acting muscarinic antagonist (LAMA).
12.1 Mechanism of Action: "Glycopyrrolate is a long-acting antimuscarinic agent which is often referred to as an anticholinergic."
Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA).
11 DESCRIPTION: "micronized formoterol fumarate [an inhaled long-acting beta2-adrenergic agonist (a LABA)]" and 12.1: "long-acting selective beta2-adrenergic agonist"
The combination of these three medications in Breztri Aerosphere works to manage symptoms of chronic obstructive pulmonary disease (COPD).
1.1: "indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients" (the provided excerpts do not separately describe symptom-management wording, but the indication supports therapeutic use in COPD maintenance).
Budesonide helps to reduce inflammation in the airways.
12.1: "Budesonide is an anti-inflammatory corticosteroid" and discussion of corticosteroid inhibitory activities against inflammatory cells/mediators.
Glycopyrrolate relaxes the muscles around the airways, making it easier to breathe.
12.1: "inhibition of the M3 receptor at the smooth muscle leading to bronchodilation"
Formoterol fumarate relaxes airway muscles by stimulating beta2-adrenergic receptors, leading to bronchodilation.
12.1: "Inhaled formoterol fumarate acts locally... as a bronchodilator" and "stimulation of intracellular adenyl cyclase... Increased cyclic AMP levels cause relaxation of bronchial smooth muscle"
Breztri Aerosphere is delivered using a pressurized metered-dose inhaler (pMDI).
11 DESCRIPTION: "Inhalation Aerosol is a pressurized metered-dose inhaler"
The Aerosphere technology is designed to deliver medication directly to the lungs with each actuation.
11 DESCRIPTION: description of priming to ensure "appropriate drug content in each actuation" and that it is an inhaler for oral inhalation delivering drug to the lungs (also mentions dependence on coordination with inspiration).
Breztri Aerosphere is manufactured by AstraZeneca.
null
Patients may experience side effects associated with inhaled corticosteroids, anticholinergics, and long-acting beta-agonists.
6 ADVERSE REACTIONS: "adverse reactions are discussed in greater detail..." (the label excerpts show class-related adverse reactions, but do not explicitly phrase this sentence; still consistent with the listed adverse reaction topics under the product).
Unsupported Statements
Breztri Aerosphere is manufactured by AstraZeneca.
The provided label excerpts do not include a manufacturer statement.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Dosage regimen: "2 inhalations twice daily, in the morning and in the evening" and "Do not take more than two inhalations twice daily."
Importance:
Moderate
Priming instructions: prime before first use ("4 sprays into the air away from the face") and re-prime if not used >7 days, is dropped, or after weekly rinsing ("2 sprays").
Importance:
Moderate
After inhalation, rinse mouth with water without swallowing.
Importance:
Moderate
Label-specific counseling for pneumonia vigilance and overlap of clinical features: "Physicians should remain vigilant" and provided pneumonia incidence/fatality context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct contraindication conflicts were identified in the provided excerpts. However, omission of specific dosing/priming/mouth-rinsing instructions and incomplete reflection of pneumonia warning content could reduce labeling fidelity for safe use messaging.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Key dosage and administration instructions (dose frequency, priming, and mouth rinsing) are not included, and pneumonia/antifungal management details are not captured.
Suggested Improvement
Add the labeled maintenance dose regimen (2 inhalations twice daily), include priming and re-priming instructions, advise mouth rinsing without swallowing, and reflect labeled warnings for oropharyngeal candidiasis management and pneumonia vigilance.